RGC Regencell Bioscience Ltd: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Regencell Bioscience is establishing scientific authority by integrating Chinese medicine methods into the fight against cognitive decline. The EV/EBITDA ratio, accounting for capital structure, visualizes this trend, where the current value is 0.00. Fundamentals are bolstered by partnerships with clinics for formula testing and the leadership of Yat-Gaya Au, who is guiding the team through the early stage of commercial market penetration.
regencellbioscience.com (RGC) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Debt to Equity Regencell Bioscience|RGC - Long-Term Debt to Equity|Short-Term Debt to Equity Regencell Bioscience Holdings Limited|RGC - Company Debts|Debt to Book Value Regencell Corp|RGC - Company Long-Term Loans and Borrowings|Company Short-Term Debts Regencell Bioscience|Quick Ratio regencellbioscience.com
- financial results and valuation multiples details:
RGC - Net Financial Result|Expected Profit Regencell Bioscience|RGC - Market Cap to Earnings|Future Price to Earnings Regencell Bioscience|RGC - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Regencell Corp|RGC - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Regencell Bioscience|RGC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth regencellbioscience.com|RGC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Regencell Bioscience
Summary company analytics:Regencell (RGC)
The EV/EBITDA multiple assesses the total enterprise value, including debt, relative to operating profit, allowing for the determination of the capital payback period excluding tax effects. The historical EV/EBITDA trend for Regencell Bioscience (RGC) on GURU.Markets, with a current value of 0.00, reflects the efficiency of the capital-intensive investments made by Regencell Bioscience (RGC) into ethical raw materials and ESG standards for neurological drug development, where stable operating cash flow is critical for servicing obligations.
Key competitors
EV/EBITDA Multiple BIIB (Biogen Corp)|Neurocrine Corp (NBIX) - Company Value to EBITDA|AXSM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACAD (acadia-pharm.com) - Enterprise Value to Operating Income Before Depreciation|XENE: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Viking Therapeutics Inc|SUPN (Supernus Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Catalyst Corp CPRX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Denali Therapeutics (DNLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HRMY (harmonybiosciences.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biohaven BHVN|Amylyx Pharmaceuticals Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|AVXL: EV/EBITDA Multiple|CBLL (ceribell.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRTA (Prothena Corporation plc) - EV/EBITDA Multiple|Alector Therapeutics (ALEC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Annexon Inc. (ANNX)|OMER - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|Total Company Value to Operating Income Before Depreciation Ratio acimmune.com (ACIU)|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|Neumora (NMRA) - Enterprise Value to EBITDA Ratio|SCLX: EV/EBITDA Multiple|TVGN - Total Company Value to Operating Income Before Depreciation Ratio|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|Company Value to EBITDA cogrx.com CGTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inhibikase Therapeutics, Inc. (IKT)|Cassava Sciences Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ASRT (Assertio)|COYA - Enterprise Value to EBITDA Ratio|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Ovid Therapeutics Inc.|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CervoMed, Inc. - Business Value to Operating Income Before Depreciation|ATHE (Alterity Therapeutics Ltd.) - EV/EBITDA Multiple|CLNN - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple PEPG|Enterprise Value to EBITDA Ratio jupiterneurosciences.com JUNS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|ANVS: Enterprise Value to Operating Income Before Depreciation|Grace Tx - EV/EBITDA Multiple|Company Value to EBITDA Firefly Neuro|KLTO (anewmeds.com) - Enterprise Value to EBITDA Ratio|NeuroSense Therapeutics Ltd. (NRSN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|MTVA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Business Value to Operating Income Before Depreciation NEUP|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Athira Pharma Inc|ADXN: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Alzamend Neuro ALZN|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Protagenic PTIX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|cortigent.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|BCLI - Enterprise Value to EBITDA Ratio|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA chromocell.com|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ITCI (Intra-Cellular Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MRNS|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Synaptogenix Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Trevena, Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vigil Neuroscience VIGL|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA cerevel.com (CERE)
